Search
Search
Rishi P. Singh, MD
Show Description +
Rishi P. Singh, MD, reviews details of the ASSESS study, which transitioned patients who had previously been treated with bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) to aflibercept (Eylea, Regeneron). The results of this study and its 24-month extension may help guide clinicians treating patients who have received previous treatments with other anti-VEGF drugs.
Posted: 5/17/2016
Rishi P. Singh, MD
Rishi P. Singh, MD, reviews details of the ASSESS study, which transitioned patients who had previously been treated with bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) to aflibercept (Eylea, Regeneron). The results of this study and its 24-month extension may help guide clinicians treating patients who have received previous treatments with other anti-VEGF drugs.
Posted: 5/17/2016
Please log in to leave a comment.